ClinicalTrials.gg

Program

lepodisiran

Also written as “LY3819469”, “Lepodisiran” and “Lepodisiran Sodium”.

Its studies are mostly in Atherosclerosis · Liver Diseases · Renal Insufficiency, led by Eli Lilly.

Furthest: phase 3, since Feb 27, 20248 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly83 open or runningphase 3since Feb 27, 2024Jun 1, 2021Mar 2027phase 1 · NCT07914738
  • Named in Eli Lilly’s own pipeline as Lepodisiran, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2021First study: phase 1 study in HealthyFirst studyNCT04914546 · 66 enrolled · United States, Singapore
  2. Oct 3, 2022Phase 2 study in Lipoprotein DisorderNCT05565742 · 320 enrolled · United States, Argentina, China and more
  3. Apr 24, 2023Phase 1 study in Renal InsufficiencyNCT05841277 · 26 enrolled · United States
  4. Jun 28, 2023Phase 1 study in HealthyNCT05932446 · 27 enrolled · Singapore
  5. Feb 27, 2024Phase 3 study in AtherosclerosisNCT06292013 · 17,300 enrolled · United States, Argentina, Australia and more
  6. Apr 1, 2025Phase 1 study in Liver DiseasesNCT06916078 · 30 enrolled · United States, Hungary
  7. May 22, 2026Phase 3 study in AtherosclerosisNCT07613294 · 252 planned · United States, Australia, Czechia and more
  8. Oct 29, 2026Phase 1 study in Lipoprotein(a)NCT07914738 · 66 planned

Ahead

  1. Mar 2027Primary completion: phase 1 study in Lipoprotein(a)NCT07914738
  2. Mar 2029Primary completion: phase 3 study in AtherosclerosisNCT06292013
  3. Dec 2029Primary completion: phase 3 study in AtherosclerosisNCT07613294

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07914738Lipoprotein(a)1Not yet recruitingMar 202766
NCT07613294Atherosclerosis · United States, Australia, Czechia and more3RecruitingDec 2029252
NCT06916078Liver Diseases · United States, Hungary1CompletedJul 13, 202630
NCT06292013Atherosclerosis · United States, Argentina, Australia and more3Active, not recruitingMar 202917,300
NCT05932446Healthy · Singapore1CompletedNov 7, 202327
NCT05841277Renal Insufficiency · United States1CompletedJan 9, 202426
NCT05565742Lipoprotein Disorder · United States, Argentina, China and more2CompletedOct 23, 2023320
NCT04914546Healthy · United States, Singapore1CompletedNov 9, 202266

How it is read

Names in the registry

  • “LY3819469”, 5 entries
  • “Lepodisiran”, 2 entries
  • “Lepodisiran Sodium”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.